In a groundbreaking advance in cancer biology, researchers at St. Jude Children’s Research Hospital have unveiled a novel vulnerability in cancers driven by mutations in the SWI/SNF chromatin-remodeling complex. This discovery centers on the gene-regulatory protein PHIP, which has been identified as an essential dependency in cancers characterized by broad inactivation of SWI/SNF components, particularly those lacking the tumor suppressor subunit SMARCB1. The findings, published in Nature Communications, illuminate previously uncharted mechanisms that sustain tumor growth and lay the foundation for future therapeutic strategies targeting PHIP.
The SWI/SNF complex plays a critical role in modulating chromatin architecture to regulate DNA access and gene expression. Mutations in the genes encoding this complex underlie approximately 25% of all human cancers, including notoriously aggressive pediatric tumors such as rhabdoid tumors. These tumors prominently feature loss of SMARCB1, an essential subunit of SWI/SNF, effectively disabling its tumor suppressor functions. Consequently, such cancers present a formidable challenge because the key mutated components are themselves lost, leaving no direct oncogenic target for conventional drug development.
In efforts to circumvent this therapeutic impasse, the investigation led by Charles W. M. Roberts, MD, PhD, sought to identify compensatory pathways and proteins on which SWI/SNF-mutant cancers become dependent. Utilizing extensive datasets from the Cancer Dependency Map, which aggregates genetic vulnerabilities across more than 1,000 cancer cell lines, the research team pinpointed PHIP as a top critical dependency in SMARCB1-deficient rhabdoid tumor models. This finding accentuates how cancer cells hijack alternative molecular machinery to sustain malignant proliferation when the canonical chromatin remodeler is incapacitated.
PHIP’s role emerged as particularly intriguing given its cooperation with the SWI/SNF complex in gene activation. Under normal conditions, SWI/SNF facilitates transcriptional activation by remodeling nucleosomes and enabling transcription factors’ access to DNA. In contrast, the NuRD complex, which frequently colocates with SWI/SNF on the genome, functions antagonistically by enforcing transcriptional repression and chromatin compaction. The balance between these opposing complexes orchestrates precise gene expression programs essential for cellular differentiation and proliferation.
The study reveals that, in the absence of functional SWI/SNF due to SMARCB1 loss, PHIP becomes indispensable for cancer cell viability by restraining NuRD-mediated chromatin silencing. This suppression enables the maintenance of gene expression profiles crucial for sustained cell division and tumor progression. Loss of PHIP, therefore, disrupts this delicate regulatory equilibrium, unleashing NuRD’s repressive capacity and leading to impaired cancer cell growth both in vitro and in patient-derived xenograft and organoid models.
Rhabdoid tumors offered a unique experimental framework for uncovering these phenomena due to their genomic simplicity. Unlike many adult cancers with complex mutational landscapes, rhabdoid tumors are largely monophenotypic, driven predominantly by SMARCB1 deletion with few concurrent genetic alterations. This “clean” genetic background allowed the research team to isolate and elucidate the mechanistic underpinnings linking SWI/SNF loss to PHIP dependency without confounding variables.
This discovery carries profound therapeutic implications. While direct pharmacologic inhibitors of PHIP do not yet exist, preliminary chemical compounds targeting this protein have been identified. The research provides a compelling rationale for the accelerated development of PHIP inhibitors as targeted therapies for SWI/SNF-mutant malignancies. Given that PHIP is overexpressed in several cancer types and correlates with poor clinical outcomes, its inhibition could represent a transformative intervention in cancers that have historically evaded effective treatment.
Moreover, the study extends our understanding of chromatin biology by highlighting the nuanced interplay between remodeling and repression complexes in oncogenesis. It underscores how cancer cells co-opt regulatory networks to circumvent genetic lesions and sustain malignant growth. Targeting these compensatory epigenetic mechanisms opens new frontiers in precision oncology, offering hope for patients with refractory tumors lacking conventional drug targets.
The researchers’ integrative approach combined functional genomics with sophisticated biological models, including organoids and patient-derived xenografts, to validate PHIP’s essential role. These models recapitulate the tumor microenvironment and heterogeneity more faithfully than traditional cell lines, bolstering the translational relevance of the findings. This methodological rigor paves the way for future preclinical testing of PHIP-targeting agents and combinatorial therapies to overcome resistance mechanisms.
Beyond its immediate therapeutic promise, the study enhances the conceptual framework of tumor suppressor gene loss and synthetic lethality. It exemplifies how loss-of-function mutations, which are challenging to target directly, can be exploited by identifying auxiliary factors that become critical dependencies for cancer cell survival. This paradigm is extending across cancer research, enabling the identification of drug targets that selectively kill tumor cells while sparing normal tissues.
The interdisciplinary collaboration involved scientists from St. Jude’s Comprehensive Cancer Center, Graduate School of Biomedical Sciences, and external partners at Washington University School of Medicine. The study also exemplifies the power of shared scientific resources such as the Pediatric Cancer Dependencies Accelerator and the Cancer Dependency Map in accelerating discovery. These collective efforts are bringing precision medicine closer to fruition by mapping the cancer cell’s Achilles’ heels.
In conclusion, this seminal work uncovers PHIP as a crucial suppressor of NuRD repression required for the growth of SWI/SNF-mutant cancers. By illuminating this previously unrecognized mechanism of chromatin regulation, the study opens promising avenues for therapeutics aimed at chromatin remodeling deficiencies—a prominent but challenging hallmark of many cancers. With continued research and drug development, targeting PHIP may soon offer hope for patients afflicted by these aggressive tumors.
Subject of Research: Cells
Article Title: PHIP suppresses NuRD to enable the growth of SWI/SNF-mutant cancers
News Publication Date: 7-Apr-2026
Image Credits: Courtesy of St. Jude Children’s Research Hospital
Keywords: Cancer, SWI/SNF complex, chromatin remodeling, PHIP protein, NuRD complex, rhabdoid tumors, SMARCB1, epigenetics, pediatric cancers, gene regulation, precision oncology
Tags: chromatin architecture and tumor growthcompensatory pathways in cancer treatmentgene-regulatory proteins in cancerNature Communications cancer researchnovel cancer vulnerabilitiespediatric cancers with SWI/SNF mutationsPHIP dependency in SWI/SNF-mutant cancersSMARCB1 tumor suppressor lossSt. Jude cancer biology discoveriesSWI/SNF chromatin-remodeling complex mutationstargeting PHIP in oncologytherapeutic targets for rhabdoid tumors
